Anatara Lifesciences Limited Stock Market Press Releases and Company Profile
Investor Presentation - Natural Alternative to Antibiotics
Investor Presentation - Natural Alternative to Antibiotics

Brisbane, June 23, 2016 AEST (ABN Newswire) - Anatara Lifesciences (googlechartASX:ANR) is pleased to release a copy of the presentation that Chairman, Dr Mel Bridges presented at the Finance News Network CEO Conference and the Gold Coast Investment Showcase this week.

Presentation Highlights Include:

- Data on the growing need for a safe and effective alternative to the use of antibiotics in the production of livestock animals and in humans

- An outline of the clear path to market for Anatara's lead compound, Detach(TM) - a safe, naturally derived alternative to the use of antibiotics to control diarrhoea, with Australian market launch for Detach(TM) in pigs planned for 2017

- A summary of the exclusive option to licence Detach(TM) for worldwide commercialisation with leading animal health company, Zoetis, and

- More information on the recently announced research and development collaboration with The La Trobe Institute for Molecular Science, aimed at developing active components within Detach(TM) for the treatment of inflammatory diseases in humans and in companion animals

The Anatara team plans a further market update and extensive investor roadshow in July.

To view the presentation, please visit:
http://abnnewswire.net/lnk/DE4473SS


About Anatara Lifesciences Limited

Anatara Lifesciences ASX ANRAnatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. 

 

https://twitter.com/anataraanr https://www.facebook.com/profile.php?id=61550997392627 https://www.linkedin.com/company/anatara-lifesciences-ltd abnnewswire.com 


Contact

Investor and Media inquiries:
Dr Mel Bridges
Chairman, Anatara Lifesciences
Phone: +61-413-051-600
Email: melbridges@parmacorp.com

Media:
Jane Lowe
IR department
Phone: +61-411-117-774



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 9) (Last 30 Days: 27) (Since Published: 4424)